BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 266,690 Shares of Catalent, Inc. (NYSE:CTLT)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its stake in Catalent, Inc. (NYSE:CTLT) by 31.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 575,446 shares of the company’s stock after selling 266,690 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.32% of Catalent worth $34,855,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CTLT. Millennium Management LLC raised its holdings in shares of Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the last quarter. ING Groep NV lifted its position in Catalent by 162.5% during the 3rd quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock worth $68,475,000 after buying an additional 699,851 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Catalent during the 2nd quarter worth about $29,172,000. Mizuho Markets Americas LLC bought a new position in shares of Catalent in the 3rd quarter valued at about $30,285,000. Finally, Bank of Montreal Can increased its position in shares of Catalent by 222.0% in the second quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock valued at $36,219,000 after acquiring an additional 444,084 shares during the last quarter.

Analysts Set New Price Targets

CTLT has been the subject of a number of analyst reports. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $63.40.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Catalent Price Performance

Catalent stock opened at $60.98 on Friday. The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of -26.88, a PEG ratio of 2.34 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50. The stock’s 50 day moving average is $59.79 and its 200-day moving average is $58.26.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm posted ($0.10) EPS. The company’s revenue was up 4.2% compared to the same quarter last year. Equities research analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.